What is NA-Semax-Amidate?

NA-Semax-Amidate is a modified Semax derivative, typically described as N-acetylated and amidated to change stability and degradation behavior. [1][2][3]

The key distinction is that parent Semax evidence does not automatically validate NA-Semax-Amidate. Small terminal modifications can change exposure, potency, tolerability, and evidence interpretation. [1][2][3]

Because direct public literature for the exact derivative is much thinner than parent Semax literature, this derivative remains a separate low-confidence entry. [1][2][3]

What NA-Semax-Amidate is investigated for

NA-Semax-Amidate evidence is grouped by practical use case and intranasal route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Cognition and focus

Intranasal

18% Insufficient

Cognition claims rely on parent-compound extrapolation, not NA-Semax-Amidate validation. [1][2][3]

Human evidence

Amidate-specific controlled human cognition evidence is not established in the cited literature. [1][2][3]

Animal / mechanistic evidence

The cognition rationale is extrapolated from Semax-family neurobiology and peptide-drug literature. [1][2][3]

Neuroprotection and stroke recovery

Intranasal

16% Insufficient

Neuroprotection and stroke recovery remain extrapolated, preclinical Semax-family claims. [1][2]

Human evidence

Amidate-specific human stroke or neuroprotection outcomes are not established in the cited literature. [1][2]

Animal / mechanistic evidence

Semax ischemic brain-injury studies provide the parent-compound rationale for neuroprotection and stroke-recovery discussion. [1][2]

BDNF and neurotrophin signaling

Intranasal

15% Insufficient

BDNF and neurotrophin signaling should be shown as parent-compound extrapolation, not direct amidate-specific proof. [7]

Human evidence

NA-Semax-Amidate-specific human neurotrophin outcomes are not established. [7]

Animal / mechanistic evidence

Semax-family work reported rapid changes in NGF and BDNF gene expression in rat glial cells, supporting the neurotrophin rationale by extrapolation. [7]

Mood and stress support

Intranasal

15% Insufficient

Mood and stress support remains a preclinical Semax-family extrapolation for NA-Semax-Amidate. [8]

Human evidence

NA-Semax-Amidate-specific controlled human mood or stress trials are not established. [8]

Animal / mechanistic evidence

A 2024 animal stress model reported antidepressant-like and antistress effects for Semax-family ACTH(4-10) analogs. [8]

Evidence snapshot

Overall confidence

Insufficient

18%

NA-Semax-Amidate has a Semax-adjacent rationale but insufficient direct public evidence. Parent Semax evidence does not validate the derivative. [1][2][3]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

10%

Human evidence

Insufficient

Direct human cognitive or neuroprotective outcomes for NA-Semax-Amidate are not established. [1][2][3]

20%

Animal / preclinical

Limited

Parent Semax literature supports plausibility, but it is not derivative-specific evidence. [1][2][3]

18%

Mechanism support

Insufficient

The mechanism is inferred from parent Semax ACTH-fragment biology, including neurotrophin, stress-response, immune-gene, and neuroprotection pathways. The amidated modification is meant to change stability or exposure. [1][2][3]

Forms & administration

NA-Semax-Amidate is tracked as an intranasal modified Semax analog. The derivative is separate from parent Semax and from injectable peptide dosing. [4][1][2]

Nasal spray

Dosing & protocols

The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.

Typical Range

Common intranasal protocols usually use 300-600 mcg per day. [4][1][2]

Frequency

Common intranasal schedules use 1-2 sessions daily. [4][1][2]

Timing Considerations

Morning or early-afternoon timing is the common anchor to avoid confusing alertness notes with sleep disruption. [4][1][2]

Cycle Length

Common intranasal blocks run 2-4 weeks before changing dose or combining with parent Semax or Selank. [4][1][2]

What to expect

First few days

Intranasal NA-Semax-Amidate may feel like daytime alertness, sharper task initiation, or a more noticeable stimulation profile than parent Semax. [1][2][3][4]

Weeks 2-4

Intranasal focus, stress response, mood, and sleep-pattern effects may become more recognizable across routine days. [1][2][3][4]

After stopping

Alertness, focus, or stress-response changes may soften over routine days after intranasal NA-Semax-Amidate use ends. [1][2][3][4]

Safety profile

NA-Semax-Amidate safety should be treated as derivative-specific: intranasal irritation, headache, stimulation, sleep disruption, and formulation identity matter. [1][2][3][4]

Common side effects

Nasal irritation [1][2][3][4]
Headache [1][2][3][4]
Overstimulation [1][2][3][4]

Cautions

Derivative-specific [1][2][3][4]
Anxiety / sleep sensitivity [1][2][3][4]
Formulation variability [1][2][3][4]

What we don't know

Derivative-specific human safety, dose-ranging, interactions, and long-term intranasal use remain poorly characterized. [1][2][3][4]

Who NA-Semax-Amidate is not for

Route-specific avoid and medical-review notes:

Pregnancy or breastfeeding
Pregnancy or breastfeeding warrants medical review or avoidance for NA-Semax-Amidate. [1][2][3][4]
Unstable anxiety or bipolar symptoms
Unstable anxiety or bipolar symptoms warrants medical review or avoidance for NA-Semax-Amidate. [1][2][3][4]
Seizure disorder without clinician review
Seizure disorder without clinician review warrants medical review or avoidance for NA-Semax-Amidate. [1][2][3][4]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

Stimulants / nootropics
Stimulants, high-caffeine products, racetams, or other alertness stacks can compound overstimulation or insomnia; this is a theoretical neuroactive caution. [1][2][3][4]
Sedatives / anxiolytics
Benzodiazepines, alcohol, sleep aids, or sedating supplements can blur anxiety, focus, and alertness tracking; this is a theoretical neuroactive caution. [1][2][3][4]
Other nasal sprays
Decongestant, steroid, or irritating nasal sprays can add dryness or change intranasal tolerability; this is a route-specific caution. [1][2][3][4]

Regulatory status

United States

In the U.S. as of 2026-06-21, NA-Semax-Amidate has no FDA-approved drug product for the reviewed intranasal route. Research-market supply and compounded preparations are separate from approval; the 503A row names the current compounding bucket. [4][5][10][11]

Route	FDA drug approval	503A compounding
Intranasal	Not Approved NA-Semax-Amidate is not FDA-approved as an intranasal drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval. [4][5][10][11]	Not Listed NA-Semax-Amidate is not in the current reviewed 503A compounding bucket for the intranasal route; compounding status is separate from FDA drug approval. [4][5][10][11]

Intranasal

FDA drug approval

Not Approved

NA-Semax-Amidate is not FDA-approved as an intranasal drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval. [4][5][10][11]

503A compounding

Not Listed

NA-Semax-Amidate is not in the current reviewed 503A compounding bucket for the intranasal route; compounding status is separate from FDA drug approval. [4][5][10][11]

International

EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. Research-market, supplement, or compounded availability should not be treated as therapeutic approval in those markets. [13][14][15][16]

Sports & competition

WADA S0 can apply to non-approved pharmacological substances that are not otherwise named. Tested athletes should not treat NA-Semax-Amidate intranasal route as athlete-cleared without sport-specific review. [6][4][5][10][11]

How it works

NA-Semax-Amidate borrows its mechanism rationale from parent Semax ACTH-fragment biology: neurotrophin signaling, stress-response pathways, immune-gene expression, and neuroprotection models. The amidated modification is meant to change stability or exposure, not create an entirely proven new pathway. [1][2][3]

That route and derivative caveat is the main point. Intranasal formulation could change absorption and tolerability, but parent Semax data do not automatically establish derivative-specific pharmacokinetics, dose response, safety, or human cognitive benefit. Direct derivative studies would be needed to separate marketing claims from biology. [1][2][3]

Research gaps & open questions

What the current literature has not yet settled about NA-Semax-Amidate:

A key evidence gap is derivative-specific pharmacokinetics. [1][2][3]

A key evidence gap is controlled human cognition or mood outcomes. [1][2][3]

A key evidence gap is intranasal tolerability and product identity testing. [1][2][3]

Common questions

Is NA-Semax-Amidate FDA-approved?

No. NA-Semax-Amidate is not FDA-approved in the U.S. for intranasal drug use; parent Semax does not create approval for this derivative. [4][5][1][2]

Is it the same as Semax?

No. It is a modified derivative, so it does not automatically borrow every parent Semax route, exposure, or outcome claim. [4][5][1][2]

Is it stronger than Semax?

Not proven. Stronger or longer-lasting claims need NA-Semax-Amidate-specific pharmacology, intranasal exposure, tolerability, and outcome evidence. [4][5][1][2]

Myths & misconceptions

Myth

Semax evidence proves NA-Semax-Amidate.

Reality

Parent evidence is useful background, not derivative-specific validation. [1][2][3]

Myth

A modified version is automatically better.

Reality

Modifications can improve stability, but they can also change exposure and safety. [1][2][3]

History & discovery

NA-Semax-Amidate emerged from research-market interest in modified Semax analogs. Its history depends on parent Semax ACTH-fragment biology, while the amidated derivative still needs its own evidence path. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty. [1][2][3]

Parent Semax work on immune genes, ischemia response, and neuroprotection supplied the biological starting point. That background explains the derivative, but it cannot prove derivative-specific exposure. [1][2][3]

NA-Semax-Amidate became a catalog term for a modified intranasal Semax-like peptide. The modification shaped claims about persistence, but direct pharmacokinetic and human outcome data remain limited. [1][2][3]

Published research 8 studies

[1]

Semax, an analog of ACTH((4-7)), regulates expression of immune response genes during ischemic brain injury in rats.

Mol Genet Genomics, 2017 Jun. animal.

[2]

Novel Insights into the Protective Properties of ACTH((4-7))PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats.

Genes (Basel), 2020 Jun 22. animal.

[3]

Correction of Lipid Metabolism Disorders in Diabetes Mellitus with Peptide Drugs.

Bull Exp Biol Med, 2020 Mar. review.

[4]

Drugs@FDA/openFDA query for NA-Semax-Amidate

U.S. Food and Drug Administration. database query.

[5]

Compounding and the FDA: Questions and Answers

U.S. Food and Drug Administration. official guidance.

[6]

The 2026 List of Prohibited Substances and Methods

World Anti-Doping Agency. regulatory.

[7]

Rapid induction of neurotrophin mRNAs in rat glial cell cultures by 'Semax'.

PubMed, 2001. in vitro.

[8]

Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress.

PubMed, 2024. animal.